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a  b  s  t  r  a  c  t
Introduction:  Regardless  of  epidermal  growth  factor  receptor  (EGFR)  mutation  status,  erlotinib  improves
survival  for  patients  with  advanced  non-small  cell  lung  cancer  (NSCLC)  after  one  or more  chemotherapy
regimens.  Enzastaurin  is  an oral  serine/threonine  kinase  inhibitor.  This  phase  II study  was  designed  to
evaluate  the  efﬁcacy  and safety  of  erlotinib  and  enzastaurin  in  NSCLC,  a combination  with  promise  to
overcome  EGFR  resistance  based  on  preclinical  models.
Methods:  Eligible  patients  with  advanced  NSCLC  (IIIB  or IV)  who  had  failed  one  or two  prior  systemic
treatment  regimen(s)  were  enrolled  and  received  erlotinib  150  mg/day  and  enzastaurin  500  mg/day  (after
a 1125-mg  loading  dose  on  day  1, cycle  1),  both  orally  in  28-day  cycles.  The  primary  endpoint  was
progression-free  survival  (PFS).
Results:  From  January  2008  to July 2009,  49  patients  were  enrolled:  29 (59%)  men  and  20 (41%)  women;
8  (16%)  were  non-smokers.  The  median  PFS  was  1.7  months  (one-sided  90%  CI:  1.5–NA)  and  median
overall  survival  (OS)  was 8.3  months  (95%  CI: 5.3–14.3).  Five  patients  had  partial  response,  for  an  overallnzastaurin
response  rate  of  10.2%;  the  disease  control  rate  was  30.6%  (responders  +  10  patients  with stable  disease).
Grade  3–4  drug-related  adverse  events  in  ≥5%  of  patients  were  diarrhea,  acne,  and nausea.  One  possibly
drug-related  death  due  to interstitial  lung  disease  occurred  during  the  study.
Conclusions: In  previously  treated,  unselected,  advanced  NSCLC  patients,  the  addition  of  enzastaurin  to
erlotinib  did  not  improve  PFS,  response,  or OS  compared  with  historical  data  of  single-agent  erlotinib,
but  was  well  tolerated.
© 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license. . Introduction
Lung cancer remains the leading cause of cancer death in
he United States, with approximately 222,520 new cases diag-
osed and 157,300 deaths in 2010 [1].  Even after response to
rst-line platinum-based chemotherapy regimens, recurrence rou-
inely occurs in patients with advanced-stage disease and choices
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Open access under CC BY-NC-ND license. beyond ﬁrst-line treatment are limited. Currently, four agents are
approved by the Food and Drug Administration for the second-
line treatment of non-small cell lung cancer (NSCLC): pemetrexed
(for nonsquamous NSCLC), docetaxel, erlotinib, and crizotinib (in a
select population only) [2–7].
Enzastaurin (LY317615) is an oral serine/threonine
kinase inhibitor that targets the protein kinase C (PKC) and
phosphatidylinositol-3-kinase (PI3K)/AKT pathways [8,9]. Enza-
staurin affects signal transduction associated with angiogenesis,
apoptosis, and cellular proliferation, inducing inhibition of tumor
growth [10–14].  PKC over-expression and increased activity have
been linked to many cancers including colon [15], renal cell [16],
hepatocellular [17], prostate [18], and lung cancers [19,20]. In
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reclinical evaluations, enzastaurin reduced cellular proliferation
nd increased apoptosis through the PI3K/AKT pathway [21],
specially in high-grade gliomas [22] and diffuse large B-cell
ymphomas [23].
A phase I dose-escalation and pharmacokinetic study of enza-
taurin in advanced cancer was conducted in 47 patients, 42 of
hom had received at least one prior chemotherapy regimen [24].
o objective responses were reported, but 21 patients had stable
isease (SD). The main grade 2 adverse events (AEs) were anorexia,
rthritis, dyspnea, neuropathy, and edema. Three patients had a
ose-limiting toxicity of QTc prolongation [24].
Single-agent enzastaurin was tested at a dose of 500 mg  orally
aily in a phase II trial of 55 previously treated patients with
elapsed stage IIIB and IV NSCLC. No objective tumor responses
ere seen, but the progression-free survival (PFS) rate at 6 months
as 13%, the median PFS was 1.8 months, and the median overall
urvival (OS) was 8.4 months. The main AEs were fatigue and QTc
rolongation, and three grade 3 AEs of ataxia, pulmonary embolism,
nd anemia were reported [25].
More pronounced single-agent activity of enzastaurin has been
een in phase II clinical trials in diffuse large B-cell lymphomas and
igh-grade gliomas [22,23,26],  but the compound did not improve
fﬁcacy in glioblastoma compared with lomustine in a phase III
tudy [27]. Combination studies with pemetrexed, gemcitabine,
nd capecitabine have been conducted without unexpected safety
ndings [28–30].
Erlotinib is an epidermal growth factor receptor (EGFR) tyro-
ine kinase inhibitor that is approved as a single agent for second-
r third-line treatment of patients with advanced or metastatic
SCLC [3].  It is a small-molecule quinazolinamine that binds the
ntracellular tyrosine kinase domain of EGFR tyrosine kinase, thus
nducing cellular cycle arrest and apoptosis. Although the efﬁcacy
s most pronounced in patients with tumors bearing an activating
GFR mutation [31], PFS and OS beneﬁts have also been reported
n patients with wildtype EGFR genes [32,33].
The complementary side-effect proﬁle and the potential mech-
nistic synergy through downstream effector molecules common
o both pathways of enzastaurin and erlotinib led to a phase I trial
f the combination, in which no unexpected safety ﬁndings were
eported [34]. This phase II study was conducted, using the dose
ecommended from the phase I study [34], to determine the efﬁ-
acy and further evaluate the safety proﬁle of the combination in
atients with previously treated NSCLC.
. Materials and methods
.1. Patient eligibility criteria
To be eligible for the study, registered as NCT00452413, patients
ust have been at least 18 years of age, had a histologic or cyto-
ogic diagnosis of advanced NSCLC (IIIB with malignant pleural
ffusion or IV), and have failed one or two prior systemic treat-
ent regimen(s) (completed at least 2 weeks before enrollment).
 performance status of 0, 1, or 2 on the Eastern Cooperative
ncology Group (ECOG) scale and a life expectancy of at least
 months were required. Prior radiotherapy was  allowed if it
nvolved < 25% of the bone marrow, was completed at least 2 weeks
efore enrollment, and there were no residual toxic effects; and
 weeks must have elapsed from prior surgery. Patients must have
ad adequate organ function including the following: bone marrow
eserve (white blood cell count ≥3.0 ×109/L, absolute neutrophil
ount ≥1.5 × 109/L, platelet count ≥75 × 109/L, and hemoglobin
10 g/dL), hepatic (bilirubin ≤1.5 times upper limits of normal
×ULN] and alkaline phosphatase, aspartate transaminase, and ala-
ine transaminase ≤2.5 × ULN or <5 × ULN with liver metastases), Cancer 78 (2012) 57– 62
and renal (serum creatinine ≤1.5 × ULN). Effective contraception
was required of patients with reproductive potential during treat-
ment and for at least 3 months after discontinuation. Patients were
excluded for inability to swallow tablets; prior use of an EGFR
inhibitor; concomitant use of carbamazepine, phenobarbital, or
phenytoin; prior systemic therapy within 30 days; serious con-
comitant systemic disorders (including active cardiac disease or
HIV); clinically active interstitial lung disease; second active malig-
nancy; or active untreated central nervous system metastases.
Each patient signed an informed consent document that was
approved locally at each treating institution. This study was con-
ducted in accordance with the ethical principles outlined in the
Declaration of Helsinki and that are consistent with good clinical
practices and applicable laws and regulations.
2.2. Objectives and treatment plan
The primary objective was to assess PFS with the combination
regimen of enzastaurin and erlotinib at the phase I recommended
doses [34] in patients with advanced NSCLC who  were treated with
one or two  prior chemotherapy regimens.
The secondary objectives were to characterize the safety and
AEs of the combination of enzastaurin and erlotinib, to evaluate
tumor response for patients with measurable disease, to evaluate
duration of response for responding patients, and to assess OS.
Enzastaurin was  taken (within 30 min  after meals) at a dose of
500 mg  (250 mg  BID) daily, after a loading dose of 1125 mg  on day
1 of cycle 1, and erlotinib at a dose of 150 mg daily (fasting). Both
drugs were taken orally in 28-day cycles until disease progression
or intolerable toxicities occurred. Doses of enzastaurin or erlotinib
could be reduced for clinically relevant treatment-related toxicity.
Generally, a 50% dose reduction of enzastaurin was speciﬁed, with
optional re-escalation if the event did not recur after 14 days, for
most grade 3 or 4 toxicities after a temporary drug hold. Enzastaurin
was discontinued for events that did not resolve within 14 days or
if a second event occurred at the reduced dose. Erlotinib interrup-
tions and/or reductions were speciﬁed for rash or diarrhea or other
clinically relevant treatment-related toxicity (with re-escalation
possible except for diarrhea). Erlotinib was discontinued for clini-
cally relevant grade 4 events, diagnosis of interstitial lung disease,
or if a second reduction was not tolerated. A reduction in one drug
did not require reduction in the other.
2.3. Baseline and treatment assessments
Within 4 weeks before the ﬁrst dose of study treatment, baseline
tumor measurement(s) using computed tomography (including
spiral CT) scans and magnetic resonance imaging were performed
on each patient and were repeated every 8 weeks (±1 week) except
in the event of a response. Conﬁrmation of response occurred
no less than 4 weeks from the ﬁrst evidence of response. Tumor
responses were measured and recorded for enrolled patients who
received at least one dose of enzastaurin or erlotinib using the
Response Evaluation Criteria in Solid Tumors (RECIST) guidelines
[35]. PFS was deﬁned as the time from the date of study enroll-
ment to the ﬁrst date of progressive disease (PD; either objectively
determined or clinical progression) or death from any cause. OS
was deﬁned as the time from the date of study enrollment to the
date of death from any cause. Duration of response was deﬁned
as the time from the date when the measurement criteria were
met for complete response (CR) or partial response (PR) (whichever
status was  recorded ﬁrst) until the date of ﬁrst observation of objec-
tively determined or clinical disease progression. AEs were graded
for enrolled patients who  received at least one dose of enzastaurin




















































Characteristic Enzastaurin and erlotinib (N = 49)
Age, years
Mean (standard deviation) 66 (9.2)








East Asian 7 (14)
ECOG performance status, n (%)
0 18 (37)
1 29 (59)
2  2 (4)
Disease stage at initial diagnosis, n (%)
IIIB 6 (12)
IV 43 (88)
Site of primary tumor, n (%)
Adenocarcinoma of the lung 32 (65)
Squamous cell carcinoma of the lung 10 (20)
Large cell lung carcinoma 1 (2)
Bronchioalveolar carcinoma 1 (2)
Other 4 (8)
Missing 1 (2)
Smoking status, n (%)
Former 35 (71)
Current 6 (12)
to PD. One patient developed interstitial lung disease after more
than 7 months on therapy, which was  considered possibly related
to treatment and was  fatal. This patient was a 78-year-old man with
Table 2
Most common AEs (in >25% of patients) of any grade regardless of causality.
Preferred term, n (%) Enzastaurin and erlotinib (N = 49)
All AEs Drug-related AEs
Diarrhea 36 (73.5) 31 (63.3)
Rash 27 (55.1) 26 (53.1)
Fatigue 23 (46.9) 17 (34.7)C. Clément-Duchêne et al.
r erlotinib before each cycle according to Common Terminology
riteria for Adverse Events (CTCAE), version 3.0 (NCI 2003).
.4. Statistical considerations
Sample size: In this study, assuming an exponential distribu-
ion for PFS, 40 events were required to detect a hypothesized
mprovement of 40% in median PFS (2.5–3.5 months) with at least
0% power using a one-sided test signiﬁcance level of 0.10. Enroll-
ent of approximately 46 patients allowed an approximately 13%
ensoring rate at the time of the ﬁnal analysis.
Efﬁcacy: Kaplan–Meier methods were used to assess PFS,
uration of response, and OS. The tumor response rates and cor-
esponding 95% conﬁdence intervals (CIs) were calculated using
n exact method [36]. Quartiles, survival rates at appropriate
ime points, and corresponding 95% CIs were calculated and
aplan–Meier curves were generated. All tests of treatment effects
ere conducted at a two-sided alpha level of 0.05 unless other-
ise stated. For the primary analysis, the one-sided 90% CI of the
edian PFS was reported for all enrolled patients who  met  inclu-
ion/exclusion criteria and received at least one dose of either
nzastaurin or erlotinib. Provided a sufﬁcient number of patients
xisted in each subgroup, PFS was analyzed for prognostic and
emographic subgroups.
Safety: Enzastaurin and erlotinib mean daily doses were sum-
arized using descriptive statistics at each tumor assessment visit
nd throughout the entire study. AEs, deaths, serious AEs, and dis-
ontinuations due to AEs that occurred during the study treatment
eriod or within 30 days of the last dose of study treatment, includ-
ng relatedness, were summarized.
. Results
.1. Patient demographics
From January 2008 to July 2009, 49 patients were enrolled and
reated in this trial. Table 1 shows the main baseline characteristics
f the patients included in the study. The median age was 67 years
range, 42–83). Most patients were men  (59%), Caucasian (78%),
nd former smokers (71%), and had a good ECOG performance sta-
us (59% with an ECOG of 1). Six patients (12%) had stage IIIB and
3 (88%) had stage IV disease. Adenocarcinoma was the most com-
on histologic type (in 65% of patients). All patients had received
ne (26 patients) or two or more (23 patients) prior chemotherapy
egimens.
.2. Drug administration
The median number of treatment cycles received was 2 (range,
–24). A total of 14 patients (28.6%) received at least 3 cycles of
herapy. Two patients had enzastaurin doses reduced due to an AE,
nd four patients had erlotinib doses reduced due to an AE. Seven
atients had both enzastaurin and erlotinib doses omitted due to
n AE.
The actual mean daily dose received was 458.1 mg/day for enza-
taurin and 132.8 mg/day for erlotinib. The relative dose intensity
f enzastaurin and erlotinib was 91.6% and 88.6%, respectively.
.3. Efﬁcacy
The median PFS was 1.7 months (one-sided 90% CI: 1.5–NA)
Fig. 1). An analysis of PFS by subgroups showed that there were
o differences according to sex, age, race, histologic type, TNM
tage, response to prior therapy, or ECOG performance status.
he only difference noted was that non-smokers had statisticallyNever 8 (16)
ECOG = Eastern Cooperative Oncology Group.
signiﬁcantly higher PFS than former and current smokers (median
PFS of 10.3 vs 1.6 months, respectively; P = 0.02).
There were no CRs and 5 PRs, for an overall response rate of
10.2%. Ten patients (20.4%) achieved SD, 21 patients (42.9%) had
PD, and 13 (26.5%) had unknown response due to discontinuation
before disease assessment or lack of measurable disease. The dis-
ease control rate (CR + PR + SD) was 30.6% (95% CI: 18.3–45.4). The
median OS was 8.3 months (95% CI: 5.3–14.3) (Fig. 2). Three patients
remained on treatment at the time of the analysis included in this
report.
3.4. Safety
Forty-three patients (87.8%) had at least one drug-related AE,
and 16 patients (32.7%) had at least a grade 3 or 4 drug-related
AE. Tables 2 and 3 show the main AEs, with any grade diarrhea,
rash, fatigue, decreased appetite, nausea, and cough being the most
common (>25% of patients) AEs regardless of causality (Table 2) and
all grade 3–5 possibly drug-related AEs listed in Table 3.
There were 3 deaths (6.1%) during the study, including 2 dueDecreased appetite 26 (53.1) 17 (34.7)
Nausea 21 (42.9) 15 (30.6)
Cough 17 (34.7) 3 (6.1)
AEs = adverse events.
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Fig. 1. Progression-free survival for all treated patients (N = 49).
Fig. 2. Overall survival for all t
Table  3
Summary of patients with maximum CTCAE grade 3, 4, or 5 possibly related to study
drug.
CTCAE term, n (%) Enzastaurin and erlotinib (N = 49)
Grade 3 Grade 4 Grade 5
Laboratory
Patients with at least one CTCAE 1 (2.0) 0 0
Hemoglobin 1 (2.0) 0 0
Nonlaboratory
Patients with at least one CTCAE 12 (20.4) 3 (10.2) 1 (2.0)
Acne 3 (6.1) – 0
Anorexia 1 (2.0) 1 (2.0) 0
Blood – Other 1 (2.0) 0 0
Cardiac ischemia/infarction 1 (2.0) 0 0
Cough 1 (2.0) 0 0
Decubitus 0 1 (2.0) 0
Dehydration 1 (2.0) 0 0
Diarrhea 3 (6.1) 0 0
Fatigue 1 (2.0) 0 0
Hypoxia 0 0 1 (2.0)
Infect (clin) – derm/skin – (nails) 1 (2.0) 0 0
Metabolic/Lab – Other 1 (2.0) 0 0
Nausea 3 (6.1) 1 (2.0) 0
Pain GI – Abdomen NOS 1 (2.0) 0 0
Pneumonitis 1 (2.0) 0 0
Rash 1 (2.0) 0 0
Syncope (fainting) 1 (2.0) 0 0
Vomiting 1 (2.0) 0 0
Weight loss 1 (2.0) – –
CTCAE = Common Terminology Criteria for Adverse Events; Infect = infection;
clin = clinical; derm = dermatology; lab = laboratory; GI = gastrointestinal; NOS = not
otherwise speciﬁed.reated patients (N = 49).
stage IV adenocarinoma and a performance status of 1. During the
30-day period after discontinuation of therapy, 8 deaths (16.3%)
occurred, of which 7 (14.3%) were due to PD and 1 was due to an
AE of superior vena caval occlusion secondary to PD. Four patients
discontinued the study due to possibly drug-related events of rash,
fatigue, and vomiting. Four patients were hospitalized for a drug-
related AE.
4. Discussion
This phase II study analyzing the efﬁcacy and safety of a
combination regimen of erlotinib and enzastaurin in previously
treated patients with advanced NSCLC resulted in a median PFS of
1.7 months, a response rate of 10.2%, and a median OS of 8.3 months.
These results are not substantially different from those reported
with erlotinib alone in a similar patient population [3].  The com-
bination was well tolerated, with three grade 3-4 drug-related AEs
(diarrhea, acne, and nausea) occurring in ≥5% of patients, although
one death from interstitial lung disease was possibly related to
therapy.
Enzastaurin, which inhibits PKC and other PKC isoforms, was
considered a promising agent to add to erlotinib. The combination
of erlotinib with the anti-VEGF agent bevacizumab has been shown
to increase response rate and PFS, but not OS, beyond that seen
with erlotinib alone (BeTa study) [37]. There is also preclinical evi-
dence supporting the ability of enzastaurin to overcome resistance
to the EGFR inhibitor geﬁtinib [38], a drug very similar to the EGFR
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This trial was conducted before the use of routine testing for
peciﬁc EGFR mutations that have a profound inﬂuence on response
o drugs such as erlotinib [31,39,40].  Although PFS and OS beneﬁt
ith erlotinib has been reported in patients who  do not harbor
hese mutations when it is given beyond ﬁrst line [32], the response
ate is low. It is highly likely that the 10% response rate seen in
his study was related to patients with tumors harboring the EGFR
utation as that mutation frequency would be expected based on
he demographics of patients enrolled (consistent with a standard
estern population) [33]. In this trial, we did not see any evidence
o support an increase in PFS or response rate beyond what would
ave been expected with single-agent erlotinib.
Enzastaurin has not demonstrated clear single-agent activ-
ty in NSCLC [25] or metastatic breast cancer [41], nor has it
emonstrated increased response or PFS when combined with
emetrexed in another NSCLC trial [42] or with gemcitabine in a
ancreatic cancer trial [43]. No beneﬁt was seen when the com-
ound was added to a bevacizumab-containing ﬁrst-line NSCLC
egimen [44]. Ongoing combination trials with the compound
nclude studies with rapamycin in preclinical head and neck cancer
odels [45], bortezomib in multiple myeloma [46], and sunitinib
n renal cell carcinoma [47].
It is possible that enzastaurin does increase efﬁcacy for a subset
f patients with NSCLC, but speciﬁc markers for efﬁcacy have yet
o be identiﬁed. The mechanism of action of enzastaurin is through
KC inhibition and downstream suppression of PI3K/AKT signal
ransduction. Although these enzymes are known to be elevated in
ung cancer, speciﬁc levels were not measured in this trial. Phos-
horylation levels of downstream molecules of PKC have been
ostulated to be potential markers of enzastaurin efﬁcacy [48].
 recent preclinical study of enzastaurin also suggests activity in
nhibiting tumor migration and invasion by targeting the urokinase
lasminogen activator receptor (u-PAR), and perhaps further devel-
pment of the compound could identify u-PAR levels as a putative
arker of enzastaurin response [49]. Other reports indicate cyclin
1 expression may  be predictive of response to enzastaurin, with
ell lines with low expression showing higher response [50]. Exten-
ive efforts to determine biomarkers of enzastaurin efﬁcacy in
varian malignancies by the Gynecologic Oncology Group were
nsuccessful as activity of the drug was low [51].
. Conclusion
The combination of erlotinib and enzastaurin was well tolerated
ut did not improve PFS, response rate, or OS beyond what would
ave been expected with erlotinib alone in unselected, previously
reated patients with advanced NSCLC. Further development of this
ompound in NSCLC is unlikely given the limited activity seen as a
ingle agent or in combination with cytotoxic chemotherapy.
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